(January and March 2022)
In a public / private partnership context, the Resistance group of team IMoST from Clermont Auvergne University (INSERM 1240), BIOPASS and BIOMARQUEURS companies designed the BIORCELL3D features. Together, they work on the development of biotechnology preclinical tools, useful for treatment optimization and diagnosis.
Adapted to 2D cell cultures of various cancer cell types.
Adapted to improve and standardize artificial tumors® reproducibility, conservation and growth.